Town Mouse, Country Mouse: adaptation and adaptability in Mus domesticus (M. musculus domesticus)

The generally accepted idea that the house mouse is a single, world-wide species which owes its success largely to commensalism with man is wrong. There are at least five European and two Asian species lumped together under the name Mus musculus, plus another fourteen Asian species in the same genus. The house mouse of western Europe is the one that has been introduced to the Americas and Australasia, as well as being domesticated in the laboratory and ‘fancy’ strains; it is properly described as Mus domesticus. A complication of this particular species is the existence of chromosomal races involving the fusion of pairs of chromosomes, apparently at random. These races seem to be reproductively isolated from normal (2n = 40) mice. They have been described in southern Europe and northern Britain. Genetical studies of wild-living mice have shown the operation of powerful natural selection, contrary to earlier assumptions that most of the polymorphic variation in the species (especially that revealed by electrophoresis) was neutral. The effects of such selection are reduced (but not eliminated) by the deme structure of established mouse populations; this social structure is much less rigid than some laboratory experiments have suggested, because of opportunism by individual mice in replacing dead or debilitated animals, and filling new niches as these become available. Virtually every mouse population is unique, since a population tends to be founded by a small group of animals drawn from a genetically variable ancestral population. This differentiation has allowed laboratory workers to develop inbred strains with characteristic properties; it has also resulted in over 130 sub-species being described from wild caught animals. A substantial proportion of these latter have probably arisen by instant sub-speciation through the founder effect. This is well illustrated by the mice of the Faroe islands, which are often quoted as standard examples of extremely rapid evolution. The adaptive properties of the house mouse that have made it such an effective pest and such a good laboratory animal have enabled it to colonize habitats as different as Antarctic tundra and tropical atolls. The species is an ideal one for the general biological task of dissecting the traits that contribute to this adaptability; the material is largely available for this task in the diversity of local forms established in different habitats and characterized genetical varieties maintained in the laboratory. More is known about M. domesticus than any other mammal, except possibly man; the time is ripe for fusing laboratory work on reproduction, mortality, and behaviour with the information increasingly coming from field studies of wild-living animals.     

Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models

Background

Angiogenesis has become an attractive target in cancer treatment. Endostatin is one of the potent anti-angiogenesis agents. Its recombinant form expressed in the yeast system is currently under clinical trials. Endostatin suppresses tumor formation through the inhibition of blood vessel growth. It is anticipated that combined therapy using endostatin and cytotoxic compounds may exert an additive effect. In the present study, we expressed and purified recombinant human endostatin (rhEndostatin) that contained 3 additional amino acid residues (arginine, glycine, and serine) at the amino-terminus and 6 histidine residues in its carboxyl terminus. The recombinant protein was expressed in E. Coli and refolded into a soluble form in a large scale purification process. The protein exhibited a potent anti-tumor activity in bioassays. Furthermore, rhEndostatin showed an additive effect with chemotherapy agents including cyclophosphamide (CTX) and cisplatin (DDP).

Methods

rhEndostatin cDNA was cloned into PQE vector and expressed in E. Coli. The protein was refolded through dialysis with an optimized protocol. To establish tumor models, nude mice were subcutaneously injected with human cancer cells (lung carcinoma A549, hepatocellular carcinoma QGY-7703, or breast cancer Bcap37). rhEndostatin and/or DDP was administered peritumorally to evaluate the rate of growth inhibition of A549 tumors. For the tumor metastasis model, mice were injected intravenously with mouse melanoma B16 cells. One day after tumor cell injection, a single dose of rhEndostatin, or in combination with CTX, was administered intravenously or at a site close to the tumor.

Results

rhEndostatin reduced the growth of A549, QGY-7703, and Bcap37 xenograft tumors in a dose dependent manner. When it was administered peritumorally, rhEndostatin exhibited a more potent inhibitory activity. Furthermore, rhEndostatin displayed an additive effect with CTX or DDP on the inhibition of metastasis of B16 tumors or growth of A549 tumors.

Conclusion

Soluble rhEndostatin exhibits a potent anti-tumor activity in mouse xenograft models and it also has an additive effect with CTX and DDP, implying possible applications in clinical settings.     

The Hegemonic Male: Masculinity in a Portuguese Town

The Hegemonic Male: Masculinity in. Portuguese Town. Miguel Vale de Almeida Providence, RI; Berghahn Books, 1996. 186 pp.     

Scaling Humanitarianism: Humanitarian Actions in a Bosnian Town

Through an ethnographic focus on humanitarne akcije in Bosnia and Herzegovina – a local form of raising monetary donations to people who need medical treatments abroad – this paper explores humanitarianism and its understandings of life. Ethnographically tracking the course of a humanitarna akcija organised in one Bosnian town, this paper makes two related points. First, it ethnographically demonstrates that lives of the ‘helpers’ and ‘helped’ in humanitarne akcije were understood as immersed in the intense talk and gossip of the town and as exposed to the sociopolitical environment troubled in the same way. Comparing this understanding of life with the international humanitarianism, this paper suggests that the notion of ‘bare life’ in international humanitarian projects in emergencies may be the product of the separation of infrastructures, which enable and manage lives of the ‘savers’ and ‘saved’. Second, those who needed help through humanitarne akcije strongly criticised the lack of organised health care and social security in Bosnia and Herzegovina that pushed them to initiate humanitarne akcije. They criticised less how other people perceived them (the terms of their sociocultural recognition) and more the shrinking public health-care insurance, unavailability of medical treatments, unequal allocation of medicines, tissues and organs, and so forth (the unjust redistribution of resources). Their dissatisfactions imply that humanitarianism as an industry of aid can be criticised for failing to intervene in the global regimes of unequal redistribution of resources in a transformative way.     

Identifying autoantibody signatures in cancer: a promising challenge

Biomarkers that show high sensitivity and specificity are needed for the early diagnosis and prognosis of cancer. An immune response to cancer is elicited in humans, as demonstrated, in part, by the identification of autoantibodies against a number of tumor-associated antigen (TAAs) in sera from patients with different types of cancer. Identification of TAAs and their cognate autoantibodies is a promising strategy for the discovery of relevant biomarkers. During the past few years, three proteomic approaches, including serological identification of antigens by recombinant expression cloning (SEREX), serological proteome analysis (SERPA) and, more recently, protein microarrays, have been the dominant strategies used to identify TAAs and their cognate autoantibodies. In this review, we aim to describe the advantages, drawbacks and recent improvements of these approaches for the study of humoral responses. Finally, we discuss the definition of autoantibody signatures to improve sensitivity for the development of clinically relevant tests.     

Effect of Pneumococcal Conjugate Vaccination in Uruguay,a Middle-Income Country

Background

In 2008, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine childhood immunization program in Uruguay, with a 2+1 schedule. In 2010, PCV13 replaced PCV7, and the same 2+1 schedule was used. The effect of these pneumococcal vaccines on the incidence of invasive pneumococcal infections (IPD) and on serotype distribution was analyzed retrospectively, based on passive national laboratory surveillance.

Methods

Data from 1,887 IPD isolates from 5 years before and 5 years after PCV7 introduction (7 before and 3 after PCV13 introduction) was examined to assess the incidence rate per 100,000 age-specific population of all IPD, PCV7-serotypes, and PCV13-serotypes associated IPD among children <2 years and 2 to 4 years old, and patients ≥5 years old. Trends of frequency for each serotype were also analyzed.

Results

Comparison of pre-vaccination (2003–2007) and post-vaccination (2008–2012) periods showed a significant decrease in IPD incidence among children <2 years old (IR 68.7 to IR 29.6, p<0.001) and children 2 to 4 years (p<0.04). IPD caused by serotypes in PCV7 was reduced by 95.6% and IPD caused by 6 serotypes added in PCV13 was reduced by 83.9% in children <5 years old. Indirect effects of both conjugate vaccines were observed among patients ≥5 years old one year after the introduction of each vaccine, in 2010 for PCV7 and in 2012 for PCV13. Nevertheless, for reasons that still need to be explained, perhaps due to ascertainment bias, total IPD in this group increased after 2007. In 2012, the relative frequency of vaccine serotypes among vaccinated and unvaccinated population declined, except for serotype 3. Non vaccine serotypes with increasing frequency were identified, in rank order: 12F, 8, 24F, 22F, 24A, 15C, 9N, 10A and 33.

Conclusion

Consecutive immunization with PCV7 and PCV13 has significantly reduced IPD in children <5 years of age in Uruguay.